GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Debt-to-EBITDA

BJDX (Bluejay Diagnostics) Debt-to-EBITDA : -0.05 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bluejay Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.11 Mil. Bluejay Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.13 Mil. Bluejay Diagnostics's annualized EBITDA for the quarter that ended in Sep. 2024 was $-4.95 Mil. Bluejay Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bluejay Diagnostics's Debt-to-EBITDA or its related term are showing as below:

BJDX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.08   Med: -0.39   Max: -0.03
Current: -0.03

During the past 5 years, the highest Debt-to-EBITDA Ratio of Bluejay Diagnostics was -0.03. The lowest was -1.08. And the median was -0.39.

BJDX's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs BJDX: -0.03

Bluejay Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for Bluejay Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics Debt-to-EBITDA Chart

Bluejay Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.72 -1.08 - -0.06 -0.04

Bluejay Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.03 -0.03 -0.06 -0.05

Competitive Comparison of Bluejay Diagnostics's Debt-to-EBITDA

For the Medical Devices subindustry, Bluejay Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bluejay Diagnostics's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bluejay Diagnostics's Debt-to-EBITDA falls into.



Bluejay Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bluejay Diagnostics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.163 + 0.19) / -9.53
=-0.04

Bluejay Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.111 + 0.13) / -4.952
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Bluejay Diagnostics  (NAS:BJDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bluejay Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bluejay Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
Executives
Svetlana Dey director, 10 percent owner 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey director, 10 percent owner, officer: Chief Technology Officer 360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally officer: CFO 66 MELANIE LANE, SYOSSET NY 11791
Jason Cook officer: Chief Technology Officer 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher officer: Chief Financial Officer 67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth director, 10 percent owner 4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder officer: Chief Financial Officer 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani director C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman director 109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase director 39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089